iOWH 032

Drug Profile

iOWH 032

Alternative Names: iOWH032

Latest Information Update: 21 Jan 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Institute for OneWorld Health
  • Developer Institute for OneWorld Health; PATH
  • Class Amides; Antidiarrhoeals; Bromobenzenes; Heterocyclic compounds; Oxadiazoles; Phenyl ethers; Small molecules
  • Mechanism of Action Cystic fibrosis transmembrane conductance regulator inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Diarrhoea

Most Recent Events

  • 04 Apr 2014 PATH & the Bill and Melinda Gates Foundation plan a phase II trial for Diarrhoea (due to cholera) in Bangladesh (NCT02111304)
  • 26 Nov 2013 The Institute for OneWorld Health & the Program for Appropriate Technology in Health complete a phase I/II trial in Diarrhoea (due to cholera) in Bangladesh (NCT01823939)
  • 21 May 2013 Phase-I/II clinical trials in Diarrhoea (due to cholera) in Bangladesh (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top